Dietary calcium and phosphorus manipulations in thyroparathyroidectomized pregnant rats and fetal liver glycogen stores
J.-M. Garel, M. Gilbert

To cite this version:
Dietary calcium and phosphorus manipulations in thyroparathyroidectomized pregnant rats and fetal liver glycogen stores

par J.-M. GAREL, M. GILBERT *

Physiologie du Développement, Université Pierre et Marie-Curie, 9, quai Saint-Bernard, 75230 Paris cedex 05,
* Laboratoire de Physiologie du Développement, Collège de France, place M. Berthelot, 75231 Paris cedex 05.

Summary. Low levels of blood glucose and hepatic glycogen in thyroparathyroidectomized (TPTX) mothers and their fetuses have been shown to increase after vitamin D₃ metabolite injection to the mothers when their plasma calcium is low or slightly elevated. To determine the putative role of calcium in these experiments, we elevated TPTX maternal plasma calcium by calcium supplementation or dietary calcium manipulations. Four hours later, glucose administration to those mothers at day 21.5 of gestation increased hepatic glycogen concentrations as well as ¹⁴C-glucose incorporation in hepatic glycogen in both mothers and fetuses. In contrast, the simultaneous treatment of TPTX mothers with calcium and glucose at day 21.5 of gestation induced marked elevations in fetal and maternal blood glucose levels 4 h later without changing hepatic glycogen stores. In fact, ¹⁴C-glucose incorporation decreased in fetal liver glycogen. Similar results were obtained in chronic experiments involving calcium supplementation with calcium lactate or the use of a calcium-rich diet. Blood glucose levels were normalized, whereas hepatic glycogen levels were unchanged in both mothers and fetuses. On the contrary, the use of a low phosphorus diet (known to increase 1,25-dihydroxyvitamin D₃ production) in TPTX mothers increased both blood glucose and hepatic glycogen concentrations in mothers and fetuses. These data suggest that 1,25-dihydroxyvitamin D₃ in TPTX mothers may act in two ways: (i) by increasing plasma calcium which would partly explain the normoglycemia, and (ii) by inhibiting the glycogenolytic effect of calcium and thus allowing hepatic glycogen stores to increase.

Introduction.

Rat fetuses from thyroparathyroidectomized (TPTX) mothers are known to exhibit decreased values of blood glucose and hepatic glycogen stores (Porterfield, Whittle and Hendrich, 1975 ; Garel and Gilbert, 1978), and grafting one parathyroid gland or injecting vitamin D₃ metabolites to TPTX mothers restores those levels in the fetus (Gilbert, Besnard and Garel, 1980). This increase in both the fetal blood glucose and the liver glycogen stores occurs in the presence of a low but slightly elevated level of maternal plasma calcium (Garel, Gilbert and Besnard, 1981). To determine the putative role of maternal plasma calcium in the normalization of fetal blood glucose and in
the marked improvement of fetal liver glycogen stores, we attempted to correct the plasma calcium level in TPTX mothers by acute experimentation involving calcium injection and by chronic experimentation using dietary calcium and phosphorus manipulations.

Material and methods.

Experimental procedures. — Unless otherwise noted, pregnant female rats of the Wistar strain were fed a commercial diet (UAR 103) and water ad libitum. The calcium, phosphorus and magnesium contents of the diets were 0.92, 0.92 and 0.15 p. 100, respectively. The vitamin D content was 4000 IU/kg. Gestational age was determined from the estimated time of ovulation. When a female rat was caged with a male between 17.00 and 09.00 h, ovulation was estimated to have occurred at 01.00 h. Pregnant rats were detected by palpation 12.5 days later. In our colony, parturition occurred after 22 days of gestation.

Pregnant females were TPTX by surgery under light ether anesthesia on day 12.5 of gestation.

- In the first set of experiments we studied the effects of glucose or calcium administration to TPTX mothers at day 21.5 of gestation. Group 1 TPTX mothers were given a single glucose load (1 ml of 50 p. 100 glucose + a tracer dose of U 14C-glucose : 25 µCi) by stomach gavage at day 21.5 of gestation and were then killed 4 h later. The pregnant TPTX control females were given the tracer dose of U 14C-glucose (25 µCi) by stomach gavage. The administration of this pulse of radio-glucose gave an indication of hepatic glycogen metabolism.

Group 2 TPTX mothers were intraperitoneally injected with CaCl2 (6 mg/100 g of body weight) at day 21.5 of gestation and, at the same time, received a tracer dose of U 14C-glucose (25 µCi) by stomach gavage; they were killed 4 h later.

Group 3 was given ad libitum a chronic calcium supplementation (1 p. 100 calcium lactate + 3 p. 100 lactose) in the drinking water from days 12.5 to 21.5 of gestation since lactose is known to increase intestinal calcium absorption (Fournier, 1954; Lengemann, Wasserman and Comar, 1959). These females were studied at 21.5 days of gestation.

- In the second set of experiments TPTX mothers were fed unbalanced calcium-phosphorus diets. Group 1 received a diet containing 0.6 p. 100 P and 1.8 p. 100 Ca, which varied from the basal UAR diet only in its calcium and phosphorus contents. Group 2 was put on a low phosphorus diet (semi-synthetic diet UAR Ref. 212 P based on the general composition of basal diet UAR 103) containing 0.2 p. 100 P and 1.2 p. 100 Ca. The pregnant females stayed on these unbalanced diets from the day of TPTX (day 12.5 of gestation) until the end of gestation (day 21.5 stage).

With these different dietary manipulations, the weight gain and the daily food intake of the TPTX mothers were roughly similar to those of the untreated TPTX mothers. The modifications caused by TPTX in pregnant rats have already been described by Garel, Gilbert and Besnard (1981): weight gain stopped the last two days and daily food intake decreased gradually the last 4 days of gestation.
Assuming a similar time lapse between the last food intake and sacrifice, we killed the mothers by decapitation between 09.00 and 10.00 h and collected a blood sample. The maternal liver was quickly removed and stored in liquid nitrogen. The fetuses were rapidly delivered and, after cleaning the axillary region, blood was withdrawn through an incision across the axillary vessels. The fetal liver was also removed quickly and stored in liquid nitrogen. Since it has been shown that a rapid drop occurs in plasma calcium and phosphate levels soon after detachment of the fetus (Garel, 1969), a different protocol was used in the studies assaying plasma calcium and inorganic phosphorus concentrations. So, after the mother was anesthetized with ether, the fetuses were excised one by one from her well-ventilated, living body by laparotomy and hysterectomy, leaving the placental circulation intact. Fetal blood samples were taken immediately with heparinized Pasteur pipettes by section of the brachial artery. At the end of the experiments, the maternal blood was removed by intracardiac puncture.

Biochemical methods. — Plasma calcium was estimated by flame photometry (Eppendorf) and plasma inorganic phosphorus by the method of Chen, Toribara and Warner (1956). Barium hydroxide-zinc sulfate filtrates of blood were used for glucose assay using the glucose-oxidase method of Huggett and Nixon (1957). Hepatic glycogen was estimated by the method of Roehrig and Allred (1974); the frozen liver was weighed and homogenized at 0 °C in a Potter-Elvehjem tissue homogenizer; an aliquot was incubated for 10 min at 55 °C with amylo a-1,4/a-1,6 glucosidase (Boehringer, Mannheim, W. Germany) and then treated by glucose-oxidase. When a tracer dose of the U 14C-glucose was administered to TPTX mothers, hepatic glycogen content and radioactivity were simultaneously determined according to the method of Chan and Exton (1976). The frozen liver was weighed and homogenized (2.5 p. 100) in bi-distilled water with a glass teflon homogenizer. 0.1 ml of homogenate was spotted on a 2 × 3-cm piece of filter paper (Whatman 3 MM chromatography paper). The papers were dropped into a beaker containing 66 p. 100 ethanol and washed 3 times (3 × 10 min). They were then rinsed briefly with acetone, dried and placed in plastic tubes containing 0.4 ml of acetate buffer (0.05 M, pH 4.5), 1.6 ml of H2O and 0.2 ml of amylo a-1,4/a-1,6 glucosidase (3 units). The tubes were put at 55 °C for 30 min to allow the glycogen to hydrolize. Glucose was determined in 0.1 ml of hydrolysate using the glucose oxidase method. One ml of hydrolysate was placed in a vial containing 10 ml of scintillation liquid (PCS Amersham Searle) and radioactivity was measured in a liquid scintillation spectrometer (Nuclear Chicago Corp., Des Plaines, Ill.).

The results, statistically analyzed using Student’s unpaired t-test to determine the significance of changes between the control and the experimental groups, were recorded as the mean ± SEM.

Results.

— Glucose or calcium administration to TPTX mothers.

Glucose administration. — The oral administration of a single load of 50 p. 100 glucose to TPTX mothers at day 21.5 of gestation increased hepatic glycogen concen-
trations 4 h later in both mothers and fetuses (table 1). Maternal and fetal blood glucose levels returned to basal values 4 h after stomach gavage with 1 ml of 50 p. 100 glucose. The $^{14}$C-glucose incorporated into hepatic glycogen increased significantly in both mothers and fetuses (table 1). The treatment did not affect plasma calcium and phosphate levels.

**TABLE 1**

Effects after 4 h of a single load of glucose given to TPTX mothers at 21.5 days of gestation

<table>
<thead>
<tr>
<th></th>
<th>Plasma calcium (mg/100 ml)</th>
<th>Blood glucose (mg/100 ml)</th>
<th>Liver glycogen (mg/g)</th>
<th>$^{14}$C-glucose incorporation into liver glycogen (cpm/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPTX</td>
<td>4.17 ± 0.51 (4)</td>
<td>65 ± 9 (4)</td>
<td>5.8 ± 1.5 (5)</td>
<td>83,176 ± 75,979</td>
</tr>
<tr>
<td>Mothers TPTX + 50 p. 100 glucose.</td>
<td>3.68 ± 0.22 (9)</td>
<td>87 ± 9 (10)</td>
<td>14.6 ± 2.0 (9)</td>
<td>467,249 ± 105,235 *</td>
</tr>
<tr>
<td>TPTX</td>
<td>40 ± 4 (19)</td>
<td>25.8 ± 3.4 (28)</td>
<td></td>
<td>374,323 ± 76,686</td>
</tr>
<tr>
<td>Fetuses TPTX + 50 p. 100 glucose.</td>
<td>45 ± 2 (42)</td>
<td>35.1 ± 2.8 (41)</td>
<td></td>
<td>577,270 ± 46,027 *</td>
</tr>
</tbody>
</table>

Means ± SEM; the number of observations is shown in brackets. Controls (untreated TPTX): $^{14}$C-glucose gavage only; Treated: $^{14}$C-glucose + 1 ml 50 p. 100 glucose by stomach gavage. * P < 0.05 from controls; no symbol: not different from controls.

**Calcium administration.** — A single calcium load (6 mg of Ca/100 g of body weight) given by IP injection significantly raised the plasma calcium level in TPTX mothers 30 min (12.82 ± 0.66 mg/100 ml) and 4 h (7.37 ± 0.47 mg/100 ml) later and induced a marked increase in maternal and fetal blood glucose levels (table 2). However, hepatic glycogen concentrations did not change significantly in either mothers or fetuses 4 h after the calcium load. In contrast, a trend to lower values was observed in the fetal liver. A significant drop of $^{14}$C-glucose incorporation into fetal liver glycogen occurred 4 h after the calcium load was given to the mother (table 2).

The repeated administration of calcium to TPTX mothers by supplementing the drinking water with calcium lactate and lactose suppressed the mortality rate at day 19.5 of gestation, but did not maintain a normal plasma calcium concentration in the mother until the last day of gestation. The maternal plasma calcium level at day 21.5 of gestation was not different from that observed in untreated TPTX mothers (table 2). This chronic calcium supplementation in TPTX mothers increased fetal weight slightly on day 21.5 of gestation, as well as maternal and fetal blood glucose levels (table 2) which were not different from those found in normal females. However, hepatic glycogen concentrations in mothers and fetuses remained at the values observed in untreated TPTX mothers (table 2).
<table>
<thead>
<tr>
<th></th>
<th>Fetal weight (g)</th>
<th>Plasma calcium (mg/100 ml)</th>
<th>Blood glucose (mg/100 ml)</th>
<th>Liver glycogen (mg/g)</th>
<th>^14C-glucose incorporation into liver glycogen (cpm/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TPTX</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mothers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPTX + a calcium load..</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPTX supplemented with Ca lactate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.94 ± 0.08</td>
<td>19 ± 2</td>
<td>28.7 ± 3.7</td>
<td>374,323 ± 76,686</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(28)</td>
<td>(19)</td>
<td>(28)</td>
<td>(28)</td>
<td></td>
</tr>
<tr>
<td>Fetuses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPTX + a calcium load..</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPTX supplemented with Ca lactate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.67 ± 0.09 **</td>
<td>52 ± 5 **</td>
<td>21.5 ± 3.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(29)</td>
<td>(29)</td>
<td>(29)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Means ± SEM; the number of observations is shown in brackets. The calcium load (6 mg Ca/100 g body weight) as CaCl₂ was given by IP injection and ^14C-glucose by stomach gavage, both at 21.5 days of gestation; the effects were studied 4 h later. Supplementation of 1 p. 100 lactate and 3 p. 100 lactose in drinking water ad libitum from 12.5 to 21.5 days of gestation. * P < 0.05 from untreated TPTX; ** P < 0.001 from untreated TPTX.
Effects on the mother. — A normal phosphorus diet (0.6 p. 100) rich in calcium (1.8 p. 100) given from day 12.5 of gestation to the end of gestation (21.5 days) to TPTX mothers improved the plasma calcium levels until day 19.5 of gestation (9.51 ± 0.77 mg/100 ml). The maternal plasma calcium level was not maintained through the last two days of gestation (fig. 1) since at term that value was not different from the value of the TPTX control mothers. However, plasma phosphate levels still decreased at day 21.5 of gestation (fig. 1), the lowest concentration occurring at 19.5 days (1.21 mg/100 ml). Blood glucose levels were normalized, but hepatic glycogen stores were not significantly increased (fig. 1).

A low phosphorus diet (0.2 p. 100 P, 1.2 p. 100 Ca) given to TPTX mothers raised both plasma calcium and blood glucose levels at 21.5 days of gestation in the mother (fig. 1). Those levels were not different from the levels of the normal females. The plasma phosphate content was sharply reduced (mean value : 1.97 ± 0.2 mg/100 ml), and the hepatic glycogen stores greatly enhanced (by 9-fold) at the same time (fig. 1). A maternal plasma phosphate level of 0.4 ± 0.05 mg/100 ml was observed at day 20.5 of gestation.

Effects on the fetus. — Fetal weight at day 21.5 of gestation was slightly improved when the TPTX mothers were fed a calcium-rich diet (Ca/P : 3). In spite of a normal blood glucose level, the hepatic glycogen stores were not increased (fig. 1). However, fetal weight was normal until day 20.5 of gestation. Body weight and liver glycogen were greatly increased in the fetuses of TPTX mothers receiving the low phosphorus diet ; blood glucose was not different from that observed in normal fetuses (fig. 1). Fetal plasma calcium concentrations were normalized at 20.5 days of gestation.
(11.9 ± 0.34 mg/100 ml) and fetal plasma phosphate levels remained high (6.03 ± 0.58 mg/100 ml) in contrast to the extremely low level of maternal plasma phosphate (0.4 ± 0.58 mg/100 ml) observed at that stage.

Discussion.

From the present results it appears that an acute load of glucose given to TPTX mothers at day 21.5 of gestation increases both maternal and fetal liver glycogen stores 4 h later as well as 14C-glucose incorporation in liver glycogen. In contrast, the simultaneous treatment of TPTX mothers with calcium and glucose did not change hepatic glycogen stores 4 h later in either mothers or fetuses. In fact, 14C-glucose incorporation was clearly reduced in fetal liver glycogen. One of the unexpected results of this acute administration to TPTX mothers was the marked increase in blood glucose levels in both mothers and fetuses. Chronic calcium administration to TPTX mothers (as calcium lactate or in a calcium-rich diet) normalized the blood glucose levels in mothers and fetuses without changing the hepatic glycogen stores in either one. In all cases, when maternal plasma calcium was raised in TPTX mothers by the use of calcium, the results were similar in mothers and fetuses. Thus, the normalization of plasma calcium concentration in the mother may partly explain the recovery of the blood glucose levels. It has been previously shown that correcting maternal hypoparathyroidism by grafting one parathyroid gland or by injecting vitamin D₃ metabolites to TPTX mothers restores fetal blood glucose to normal and induces a twofold increase in fetal liver glycogen stores (Garel, Gilbert and Besnard, 1979 ; Gilbert, Besnard and Garel, 1980). These effects are not due to the nutritional status of the mother (Gilbert, Besnard and Garel, 1980) ; the fact that fetal liver glycogen stores are unchanged after maternal dietary restriction is well known. It is difficult to explain our results, but some speculation can be made. The parathyroid hormone has been shown to stimulate hepatic glucose production and gluconeogenesis in vitro and in vivo (Moxley et al., 1974 ; Hruska et al., 1979). The effect observed in vivo is specific to the entire molecule (PTH 1-84) since the synthetic NH₂-terminal tetracontapeptide (PTH 1-34) has no effect (Hruska et al., 1979) ; however both molecules are equally effective in raising plasma calcium. Thus, the high blood glucose levels occurring in our experiments after calcium treatment were probably not related to an increase in gluconeogenesis. In response to the rise in both blood calcium and glucose, the reduced circulating levels of insulin probably increased, whereas glucagon decreased. In such conditions, a glycogenic effect should be observed. However, that was not the case since 14C-glucose incorporation decreased in the liver. Available evidence suggests that calcium enhances glycogenolysis by acting on phosphorylase, an enzyme which was shown to be calcium-sensitive in vitro (Keppens et al., 1977 ; Van de Werve et al., 1977). Thus, our results support the view that parathyroid hormone or vitamin D₃ metabolites might act in two different ways : (i) by restoring the plasma calcium levels to normal, the calcium per se being partly the cause of the normoglycemia ; (ii) by inhibiting the glycogenolytic effect of calcium and raising hepatic glycogen stores.

Using a low phosphorus diet we normalized the blood glucose level and also greatly increased hepatic glycogen stores in both mothers and fetuses. This finding on
hepatic glycogen levels contrasts with those obtained with the calcium-rich (1.8 p. 100) diet containing a normal phosphorus level (0.6 p. 100). Fetal weight was also markedly improved by the low phosphorus diet given to TPTX mothers. The results obtained by this diet mimicked those observed after injection of 1,25-dihydroxyvitamin D₃ to TPTX mothers (Garel, Gilbert and Besnard, 1979). Our data agree with previous findings since TPTX rats placed on a low phosphate diet can amplify their production of 1,25-dihydroxyvitamin D₃ (Tanaka and de Luca, 1973) and augment total circulating 1,25-dihydroxyvitamin D₃ fivefold (Hughes et al., 1975). One interesting finding in the group on the low phosphorus diet was the high plasma phosphate maintained by the fetus when maternal phosphate level was extremely low.

Acknowledgements. — This work was supported by a grant from the Institut National de la Santé et de la Recherche Médicale (ATP 56-78-88, contract No 5).

Résumé. Il a été montré précédemment que la glycémie et les réserves en glycogène sont profondément diminuées chez la ratte thyro-parathyroïdectomisée (TPTX) et ses fœtus, et que l’injection de métabolites de la vitamine D₃ permet de corriger ces effets en présence d’une calcémie maternelle basse bien qu’augmentée. Pour mieux évaluer le rôle éventuel du calcium dans ces expériences, on a dans le présent travail administré de manière aiguë ou chronique du calcium chez la ratte TPTX.

L’ingestion de glucose à 21,5 jours de gestation chez la ratte TPTX entraîne 4 h après une augmentation des réserves en glycogène hépatique à la fois chez la mère et le fœtus. De plus, l’incorporation de glucose ¹⁴C dans le glycogène hépatique de la mère et du fœtus est augmentée. Or, l’administration simultanée à la ratte TPTX de calcium et de glucose à 21,5 jours est suivie 4 h après d’une augmentation très importante de la glycémie maternelle et fœtale sans que les réserves en glycogène de la mère et du fœtus ne soient modifiées. Au contraire, l’incorporation de glucose ¹⁴C dans le glycogène hépatique du fœtus est diminuée. Des résultats similaires sont obtenus par le traitement chronique de la ratte TPTX, qu’il s’agisse d’une supplémentation en lactate de calcium ou de l’administration d’un régime riche en calcium. Dans ces deux cas, les glycémies maternelles et fœtales font retour à la normale, mais les réserves en glycogène hépatique ne sont pas affectées que ce soit chez la mère ou le fœtus. Au contraire, l’utilisation d’un régime pauvre en phosphore (situation qui est connue pour augmenter le taux de production de 1,25-dihydroxycholécalciférol) chez la ratte TPTX permet d’augmenter très nettement les réserves en glycogène hépatique chez la mère et le fœtus et de normaliser les glycémies maternelles et fœtales.

Ces résultats semblent suggérer que le 1,25-dihydroxycholécalciférol pourrait agir dans nos expériences de la manière suivante : — en augmentant la calcémie, ce qui expliquerait en partie l’augmentation de la glycémie ; — d’autre part la présence du 1,25-dihydroxycholécalciférol s’opposerait à l’effet glycogénolytique du calcium permettant ainsi la mise en réserve du glycogène.

References


